Daiichi Sankyo Company Limited (D4S MU) stock market data APIs
€16.2861
-0.19(-1.2%)
as of February 19, 2026
Try our APIs with
free plan!
Daiichi Sankyo Company Limited Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for D4S.MU.
Prev. Close
16.2861
Open
16.0965
High
16.3614
Low
16.0881
52 wk Range
15.53-23.7283
Market Cap
38 045 M
Dividends (Yield)
0.5932
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Daiichi Sankyo Company Limited data using free add-ons & libraries
Get Daiichi Sankyo Company Limited Fundamental Data
Daiichi Sankyo Company Limited Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-01-30
- EPS/Forecast: 30.29
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Company Limited News
New
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
TOKYO & BASKING RIDGE, N.J., February 20, 2026--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global He...
European Stocks Lower in Thursday Trading; ECB Says Economy Resilient but Outlook Remains 'Challenging'
The European stock markets look set to close lower Thursday trading as The Stoxx Europe lost 0.5%, G PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ...
BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics
AI Foundation Models to Enable Precision ADC Clinical Development and Response Intelligence WALTHAM, Mass., February 17, 2026--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation ...
Get Daiichi Sankyo Company Limited fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
